Drug Landscape ›
Haloperidol-Haloperidol ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 87
Most-reported reactions
Agitation — 13 reports (14.94%) Neuroleptic Malignant Syndrome — 11 reports (12.64%) Dehydration — 9 reports (10.34%) Drug Interaction — 9 reports (10.34%) Dystonia — 8 reports (9.2%) Renal Failure Acute — 8 reports (9.2%) Toxicity To Various Agents — 8 reports (9.2%) Anxiety — 7 reports (8.05%) Hyponatraemia — 7 reports (8.05%) Nausea — 7 reports (8.05%)
Source database →
Haloperidol-Haloperidol in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Haloperidol-Haloperidol approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Haloperidol-Haloperidol in United States?
New York State Psychiatric Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.